| 规格: | 98% |
| 分子量: | 232.2 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
Background:
QLT0267 is an inhibitor of integrin-linked kinase (ILK; IC50= 26 nM).1It is greater than 10-fold selective for ILK over cyclin-dependent kinase 1 (Cdk1), Cdk2, and Cdk5, as well as greater than 1,000-fold selective for ILK over C-terminal Src kinase (CSK), DNA-PK, Pim-1, Akt, PKC, and casein kinase 2 (CK2), at 10 mg/ml. QLT0267 inhibits the growth of NPA187 papillary thyroid cancer cells (IC50= ~3 µM) and induces apoptosis in NPA187, DRO, and K4 cancer cell lines.In vivo, QLT0267 (100 mg/kg) reduces tumor growth in a DRO mouse xenograft model. It also reduces tumor volume and intratumoral blood vessel mass in a U87MG glioblastoma mouse xenograft model.2
1.Younes, M.N., Kim, S., Yigitbasi, O.G., et al.Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancerMol. Cancer. Ther.4(8)1146-1156(2005) 2.Edwards, L.A., Woo, J., Huxham, L.A., et al.Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)Mol. Cancer Ther.7(1)59-70(2008)
m.cnreagent.com